Two More Patent Allowances for Glytec’s Diabetes Software

MARCH 28, 2018 Two More Patent Allowances for Glytec’s Diabetes Software The latest allowances from the USPTO address systems and methods specific to the dosing of subcutaneous insulin for acute and chronic care. Waltham, MA — The United States Patent and Trademark Office (USPTO) has issued two more patent allowances for Glytec’s FDA-cleared proprietary software used by healthcare providers to...
Read More

Glytec Announces Fourth FDA 510(k) Clearance for Its Market-Leading Diabetes Therapy Management Software

AUGUST 16, 2017 Glytec Announces Fourth FDA 510(k) Clearance for Its Market-Leading Diabetes Therapy Management Software The company’s eGlycemic Management System® featuring Glucommander™ has the broadest indications for use of any decision support solution for insulin titration. WALTHAM, MA — The pioneer of diabetes therapy management software, Glytec announces its fourth FDA clearance, adding...
Read More

Glytec Receives Five Additional Patent Allowances for its Diabetes Therapy Management Software

JUNE 29, 2017 Glytec Receives Five Additional Patent Allowances for its Diabetes Therapy Management Software Poised to address diabetes on a global scale, the company expands its intellectual property protections in the United States and abroad. WALTHAM, MA — Glytec, the healthcare company behind a market-leading software solution for personalized diabetes therapy management, announces five new...
Read More

Glytec Grows its Patent Portfolio with Another Notice of Allowance for its Precision Diabetes Management Technologies

DECEMBER 15, 2016 Glytec Grows its Patent Portfolio with Another Notice of Allowance for its Precision Diabetes Management Technologies This latest notice of allowance from the United States Patent and Trademark Office deepens Glytec’s intellectual property protections and further validates its leadership stature in the healthcare market. Waltham, MA — Glytec today announces another notice of...
Read More

Glytec Receives Three Additional Patent Notices of Allowance from USPTO for its Breakthrough Diabetes Technologies

SEPTEMBER 27, 2016 Glytec Receives Three Additional Patent Notices of Allowance from USPTO for its Breakthrough Diabetes Technologies The notices further validate Glytec’s position as a leader in advanced technologies and innovations for glycemic management. Waltham, MA — Glytec today announces notices of allowance received from the United States Patent and Trademark Office (USPTO) for three...
Read More